Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,723.32
+14.230.53%
Number of Gainers:57
Number of Losers:40
Number of Flat:1
PE:- -
High:2,727.96
Open:2,708.94
Low:2,708.43
Close:2,708.99
Volume:609.01M
Turnover:123.98B
Market Cap:49.81T
Float Cap:46.34T

Loading ...

This Fidelity Manager Likes Coca-Cola, Keurig Dr Pepper, and Other Consumer Staples Bargains

Dow Jones
·
Oct 01

X-Rite Pantone Launches Spectura Portable Sphere Spectrophotometer Platform

Reuters
·
Oct 01

Chip Giants Surge Together as KOSPI Jumps Nearly 2%, Ending Three-Day Losing Streak

Deep News
·
Oct 01

Micron’s $73 Billion Cash Mountain Is About To Move — CFO Signals Bigger Buybacks: ‘We Have the Ability And the Intent…’

Benzinga Earnings
·
Oct 01

Thales - Thales and Google Strengthen Their Partnership to Secure Agent-Based AI

THOMSON REUTERS
·
Oct 01

Tesla New Registrations in Sweden +38.4% Year-on-Year in September, Compiler Mobility Sweden Says

THOMSON REUTERS
·
Oct 01

Eaton - Expands Manufacturing Facility in Schrems, Austria on October 1, 2026

THOMSON REUTERS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Goldman Sachs pushes back second Fed rate hike forecast to December, saying need for further tightening is diminishing

Deep News
·
Oct 01

LIVE Markets-Europe Before the Bell: Futures in the Red, Semis Set for Boost

Reuters
·
Oct 01

Analyst Maintains Hold on Enbridge, Citing Defensive Assets but Limited Upside Amid Pipeline Competition and Balance Sheet Constraints

TIPRANKS
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01

Starz Entertainment Corp. - Customers Lose Access After Failed Negotiations with Verizon

THOMSON REUTERS
·
Oct 01

Top 3 Founder Run Stocks To Watch In October 2026

Simply Wall St.
·
Oct 01

BlackRock American Income Trust Reports 70,845,138 Total Voting Rights as of Sept. 30

Reuters
·
Oct 01